Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 46914.36 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 934.96 Crore, up 4.52 % from last quarter Total Income of Rs 894.55 Crore and up 37.20 % from last year same quarter Total Income of Rs 681.44 Crore. Company reported net profit after tax of Rs 260.41 Crore in latest quarter.
Investment Rationale
The brokerage values GLAND at P/E multiple of 31x to arrive at TP of INR3,280. It remains positive on the stock on the back of: a) niche pipeline, b) enhanced offerings/adding newer geographies in the RoW segment, c) operating cost efficiency, d) consistent compliance, and e) enough war chest to tap inorganic opportunities
Promoter/FII Holdings
Promoters held 58.3 per cent stake in the company as of March 31, 2021, while FIIs held 11.9 per cent, DIIs 11.3 per cent and public and others 18.6 per cent.
(Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
